Pharmaceutical composition for treating fibrosis

Abstract

To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts without injuring alveolar epithelial cells and thus inhibits lung fibrosis. A pharmaceutical composition for treating fibrosis that comprises a compound represented by formula (I) or (II), a pharmaceutically acceptable salt thereof, or a solvate of the same. [In formula (I): R1 represents an optionally halogenated C1-4 alkyl group; and l represents an integer of 3-6. In formula (II): n represents an integer of 8-12.].

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis; IPF) is a chronic disease with poor prognosis, and the median survival period after diagnosis is very short, ranging from 2.8 to 4.2 years. So far, steroids and immunosuppressants have been used as therapeutic drugs for IPF, but large-scale clinical trials have reported no effect. In addition, two new drugs, pirfenidone and nintedanib, have been marketed in recent years as anti-fibrotic drugs. These medicines have suppressed the decline in forced vital capacity (FVC) of IPF patients in clinical trials (Non-Patent Documents 1 to 3), but their effectiveness in long-term use is unclear. In addition, both drugs cause frequent and severe side effects, especially gastrointestinal disturbances, which have become a problem (Non-Patent Documents 2 and 3). Therefore, it is very important to de...

AI Technical Summary

Problems solved by technology

These medicines have suppressed the decline in forced vital capacity (FVC) of IPF patients in clinical trials (non-patent literature 1 to 3), but their effectiveness in long-term use is unclear.

In addition, both drugs cause frequent and serious side effects, especially gastrointestinal disturbances, which have become a problem (Non-Patent Documents 2 and 3)

Images